566 results about "Kinase protein" patented technology

The invention discloses a receptor-like protein kinase gene containing a Malectin-like structural domain and associated with the heat resistance character of cotton, and belongs to the field of biotechnology application. The invention provides a cDNA (complementary deoxyribonucleic acid) sequence (SEQ ID NO.1) and a genomic sequence (SEQ ID NO.2) of the gene in allotetraploid upland cotton, 456 upland cotton varieties can be divided into two haplotype promoters according to a heat-resistant character GWAS associated site A11: 20036111, the sequence of a CC heat-labile haplotype promoter is shown as SEQ ID NO.3, and the sequence of a TT heat-resistant haplotype promoter is shown as SEQ ID NO.4. The invention also provides a method for preparing the promoter. The gene provided by the invention is obtained by cotton variety re-sequencing and whole genome association analysis, and is significantly associated with the heat-resistant character of cotton, and two promoter haplotypes of the gene are utilized to distinguish heat-resistant and non-heat-resistant haplotypes. The gene has important research value and application prospect in improvement of the heat-resistant character of cotton and cultivation of new heat-resistant varieties of cotton.

Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure provides methods of inhibiting RAN protein translation by contacting a cell with an effective amount of an inhibitor of eIF2 phosphorylation or an inhibitor of protein kinase R (PKR). In some embodiments, methods described by the disclosure are useful for treating diseases associated with RAN protein translation, such as certain neurodegenerative diseases.

The invention belongs to the technical field of plant heredity and genetic engineering, and particularly relates to a wheat saline-alkaline tolerant protein kinase gene TaCRCK and application thereof. Specifically, the invention discloses a wheat saline-alkaline tolerant protein kinase gene TaCRCK, and the nucleotide sequence of cDNA of the gene is as shown in SEQ ID NO. 1. The invention also discloses a plant expression vector containing the gene TaCRCK and application of the gene and the plant expression vector in cultivation of saline-alkali resistant plants. Tests prove that silent expression of the gene promotes the resistance of wheat to saline-alkaline stress, and the saline-alkaline tolerance of transgenic plants is obviously improved. The gene has a negative regulation effect on the salt and alkali tolerance of plants, provides a new tool and method for improving the salt tolerance of crops by using a genetic engineering means, and has important scientific significance and application prospects.

The invention relates to application of mitogen-activated protein kinase PiPmk1 in screening molecules for inhibiting formation of a phytophthora infestans infection structure. The invention finds that the molecular marker plays a key role in the development of a phytophthora infestans cyst bud tube and / or the formation of an infection structure, which indicates that the molecular marker has the potential of serving as a target for inhibiting phytophthora infestans infection, and a corresponding molecular screening method and a generative prediction model are further developed and utilized; rapid and accurate prediction and screening of phytophthora infestans infection inhibitory molecules are realized, the research and development period and cost are greatly shortened, and a new thought and a new method are provided for development of accurate targeted green pesticides.

The invention belongs to the technical field of biological medicines, and particularly discloses application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. According to the application of the (E)-BCI hydrochloride in preparation of the medicine for treating sepsis, by inhibiting the activity of bispecific phosphatase 6, a mitogen activated protein kinase signal channel is regulated and controlled, and the expression level of inflammatory factors IL-1beta and TNF-alpha is reduced. The invention discloses application of (E)-BCI hydrochloride in preparation of drugs for treating sepsis, BCI enters from a new target for regulating inflammation and immune balance through a targeted DUSP6 / MAPK signal channel, a non-antibiotic-dependent drug is provided for treatment of sepsis, and the (E)-BCI hydrochloride is especially suitable for systemic inflammatory response syndromes caused by infection, operations, wounds and other inducements, and has a wide application prospect. Wide clinical application prospects are realized.

The invention belongs to the field of plant genetic engineering, and discloses a key gene OsHPCA1 for positively regulating salt stress and oxidative stress tolerance of rice. The gene (with the login number of Os05g40770) encodes a receptor protein capable of specifically sensing hydrogen peroxide, and belongs to a leucine repeat receptor-like protein kinase (LRR-RLKs) family, wherein the family is the largest subfamily in the receptor-like protein kinase (RLKs). The OsHPCA1 responds to salt and oxidative stress signals, and the salt tolerance and oxidative stress resistance of the rice are positively regulated and responded. The OsHPCA1 overexpression rice strain shows very strong salt tolerance; and the OsHPCA1 knockout strain oshpca1 is more sensitive to salt stress. The OsHPCA1 protein encoded by the OsHPCA1 gene and rich in leucine repeat receptor-like protein kinase can positively regulate and control the activity of catalase C (CatC) in rice and enhance the removal efficiency of H2O2 under salt stress, so that the salt tolerance of rice is improved. When the OsHPCA1 is overexpressed, the activity of CatC in the overexpressed strain OsHPCA1 is obviously increased, the H2O2 removal capability is enhanced, and the salt tolerance and oxidative stress tolerance of the rice are improved.

The present invention relates to compounds of formula (I) below, or any one of its pharmaceutically acceptable salts: [Formula 1] JPEG2023523788000127.jpg41170 where R 1 is (C1-C6) alkyl group, spiro (C5-C 11 ) bicyclic rings, fused phenyl groups, substituted phenyl groups, R'-L- groups, where L is either a single bond or a (C1-C3) alkanediyl group, and R' is a (C3-C8) cycloalkyl group, a bridged (C6-C 10 ) cycloalkyl group, (C3-C8) heterocycloalkyl group, or (C3-C8) heteroaryl group, or R'-L- group, where L is a (C1-C3) alkanediyl group and R' is an optionally substituted phenyl group, and R 2 represents a hydrogen atom or a (C1-C3) alkyl group. The present invention further relates to compositions comprising the compound of formula (I), as well as methods for preparing the compound and synthetic intermediates thereof. The present invention also relates to the compound for use as a pharmaceutical, in particular for treating and / or preventing cognitive impairment associated with Down's syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 deficiency disorders; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; folate and methionine metabolism disorders; osteoarthritis; Duchenne muscular dystrophy; some cancers; neuroinflammation, anemia, and viral and unicellular infections, and for regulating body temperature.

Disclosed are a series of isoquinolone derivatives as ROCK protein kinase inhibitors and uses thereof in preparing medicaments for ROCK protein kinase inhibitor-related glaucoma or ocular hypertension diseases. Specially, disclosed are a compound of formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.

The invention relates to RIP1 inhibiting compounds and methods of making and using the same. In particular, disclosed herein are kinase inhibitory compounds, such as receptor interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations may be used to treat or prevent kinase-related diseases or disorders, particularly RIP1-related diseases or disorders.

The invention relates to the technical field of biological active peptides, in particular to a method for rapidly and effectively screening light protection active peptides from collagen hydrolysate. The invention relates to an application of a photoprotective polypeptide in preparation of a product. The product has at least one of the following purposes: (1) maintaining or increasing the water content of skin; (2) preventing and / or slowing down skin aging; (3) prevention and / or alleviation of skin UVB injury; and (4) promoting healing of skin wounds or wound surfaces. Two key signal factors (NF-kB, AP-1) and a key matrix metalloproteinase (MMP-9) are screened from a mitogen-activated protein kinase (MAPK) and nuclear factor-kB (NF-kB) pathway to be used as docking targets, and a mimic peptide and the three targets act synergistically to make up for the defect that a single target screening peptide is difficult to comprehensively cope with a light damage multivariate pathway, so that the application of the mimic peptide to the light damage multivariate pathway is realized, and the application of the mimic peptide to the light damage multivariate pathway is realized. And the collagen peptide with excellent light protection activity is obtained through screening.

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK1 and MKK7. In formula (I), especially, Rw is —NR10SO2R12; either a) Rx and Ry are F and Rz and Rzz are H; or b) Rx, Ry and Rzz are independently halogen and Rz is H; R5 is substituted phenyl or pyrimidinyl.

The present invention relates to compounds having cyclin-dependent kinase (CDK)-inhibitory functions and / or pharmaceutically acceptable salts thereof, the use of these compounds as pharmaceutically active agents, especially for the prophylaxis and / or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing such compounds.

The invention discloses an application of a GhMKK5 gene in improving the disease resistance of cotton verticillium wilt, and belongs to the field of biotechnology application. The GhMKK5 gene disclosed by the invention is used for coding a mitogen activated protein kinase kinase. The invention provides a full-length CDS nucleotide sequence and an amino acid sequence of GhMKK5 in an upland cotton genetic standard line TM-1. The gene is expressed in all tissues of cotton, and is induced by verticillium dahliae to realize obvious up-regulation expression. The verticillium wilt resistance of cotton is reduced by silencing the gene in cotton, and the disease resistance of arabidopsis thaliana is improved by overexpressing the gene in arabidopsis thaliana, which indicates that the gene plays an important role in cotton verticillium wilt resistance.

The invention belongs to the technical field of plant genetic engineering, and particularly discloses application of an important member of a potato mitogen-activated protein kinase (MAPK) family, namely an StMKK9 gene in regulation and control of maturity and cold resistance of potatoes. CDNA of a cultivar Desiree leaf is used as a template, the potato StMKK9 gene is separated and cloned, an over-expression vector is constructed, and the over-expression vector is used for expression of the potato. Genetic transformation of the potatoes is further carried out, it is found that the overexpressed StMKK9 gene can promote prematurity of the potatoes, meanwhile, the cold resistance of potato plants can be improved, and a new genetic material and a theoretical basis are provided for analysis of a potato tuberization molecular mechanism and improved breeding of the potatoes.

The present invention provides a method for modulating the alkaloid content of a plant (e.g. a tobacco plant), the method comprising modifying said plant by modulating the activity or expression of a protein kinase. The present invention also provides for the use of a protein kinase for modulating the alkaloid content of a plant, as well as tobacco cells, plants, plant propagation materials, harvested leaves, processed tobaccos, or tobacco products obtainable in accordance with the invention.

The application relates to the field of agricultural disease control technology, and particularly relates to the use of indole compounds and pharmaceutically acceptable salts, solvates, crystal forms, prodrugs, stereoisomers and tautomers thereof for preparing a medicine for inhibiting pathogenic key protein kinase CgSlt2 of pathogenic fungi. The application first proposes a new type of CgSlt2-targeted inhibitor, specifically, indole compounds ((S)-N-(1-(1H-indol-3-yl)-4-(methylamino)-4-oxobutan-2-yl)-8-bromo-1,6-naphthyridine-2-carboxamide) and ((S)-N-(2-((1H-indol-3-yl)-1-(methylamino)-1-oxopropyl)-8-bromo-1,6-naphthyridine-2-carboxamide) are used as CgSlt2 inhibitors, have the characteristics of high target specificity and high activity, and exhibit excellent pathogenicity inhibition of a strain of the complex group of Colletotrichum gloeosporioides.

Disclosed herein are compositions and methods for activating a light responsive modified protein kinase R-like endoplasmic reticulum kinase (PERK) and the Integrated Stress Response (ISR) pathway in a cell.

Developed and provided is a method for creating an area-restricted search type arthropod which belongs to the class Insecta or Arachnida and has high selection efficiency.　An area-restricted search type arthropod having high selection efficiency is created by measuring the expression level of a cGMP-dependent protein kinase gene in each test individual in a homogeneous individual group and selecting a test individual of which the expression level is significantly higher than that of a wild-type control individual.

The present invention relates to an aryl substituent-containing degradation agent for cyclin-dependent kinase 12 / 13 (CDK12 / 13), a preparation method therefor, and a pharmaceutical composition and use thereof. The degradation agent for CDK12 / 13 of the present invention has a structure represented by formula (I). The compound can be used as a protein kinase degradation agent, and can effectively and highly selectively degrade a CDK12 / 13 protein and inhibit proliferation, migration, and invasion of various tumor cells.

The present invention relates to a nucleic acid molecule capable of controlling innate immunity by RNA and, more specifically, to a short duplex hairpin RNA (sdhRNA) that binds to protein kinase R (PKR), which is activated upon recognition of RNA, thereby inhibiting the activity of PKR and suppressing PKR-mediated innate immunity and which, when introduced into the 3'-UTR of mRNA, can increase the expression level of an antigen. The sdhRNA motif according to the present invention inhibits the activity of protein kinase R (PKR) by binding to PKR activated by recognizing RNA. Therefore, when administered into cells in combination with exogenous RNA or as an insert into the 3'-UTR of mRNA, the sdhRNA motif exhibits the effect of reducing RNA-indued PKR activation, mitigating RNA-induced cell death, and downregulating the expression of interferon-stimulated gene (ISG) as well as improving the expression efficiency of a protein encoded by the mRNA. With the effects, the motif is applied to various RNA-based uses, for example, vaccines, in vivo / ex vivo gene therapeutic agents, and the like.

This invention discloses compounds of Formula I, or pharmaceutically acceptable salts, isomers, racemates, precursors, or solvates thereof. Compounds of Formula I exhibit excellent inhibitory activity against RSK protein kinase, thus showing promise for development into drugs targeting RSK.

The invention relates to a preparation method and application of a novel CDK12 / 13 covalent inhibitor substituted by a fused ring structure or a pharmaceutical composition of the novel CDK12 / 13 covalent inhibitor. The novel CDK12 / 13 covalent inhibitor with the substituted ring-fused structure has a structure as shown in a formula (I), can be used as a protein kinase inhibitor, can effectively and highly selectively inhibit the activity of CDK12 / 13 protein kinase, and can inhibit proliferation, migration and invasion of various tumor cells. # imgabs0 #

The present disclosure relates to methods of treating solid tumors by administering a therapeutically effective amount of a mitogen-activated protein kinase (MAPK) inhibitor having the structure of Compound (I): (Compound I), or a pharmaceutically acceptable salt thereof.

The present invention relates to a novel compound and a pharmaceutical composition comprising the same as an active ingredient. The novel compound, which is obtained by means of carrying out chemical modification in a mother structure showing excellent AMP-activated protein kinase (AMPK) activation efficacy and in silico binding capacity, enables effective prevention or treatment of degenerative neurological disorders by means of effectively inducing AMP-activated protein kinase enzyme activation.

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I:or a pharmaceutically acceptable salt, wherein the variables are as defined herein.Moreover, The compounds of this invention have formula I-A:or a pharmaceutically acceptable salt, wherein the variables are as defined herein.

Compositions and methods for the treatment of retinal degeneration are provided. In one aspect, provided herein is adeno-associated virus (AAV) vector comprising an AAV capsid having encapsidated therein a vector genome comprising AAV inverted terminal repeat (ITR) sequences, a human protein kinase B (AKT) coding sequence, and expression control sequences that direct expression of AKT in a host cell.

Provided is a 1H-imidazo[4,5-h]quinazoline compound of formula (I). The compound is a broad spectrum inhibitor having strong activity for cyclin-dependent kinase (CDK) and is applicable in treating cell proliferative disorder

The invention relates to a compound used as a CDK2 / 4 protein kinase inhibitor and application thereof. Specifically, the invention discloses a compound shown as a formula I, or pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, solvate, isotope compound or prodrug thereof, and the definitions of all groups and substituent groups are described in the specification. The compound provided by the invention can be used as an inhibitor of cyclin dependent kinase (CDK), and is used for preventing or treating cell proliferative diseases and symptoms including various cancers, in particular for regulating and / or treating related diseases caused by overexpression and / or abnormal activity of the cyclin dependent kinase CDK2 / 4. # imgabs0 #

The present application relates to plant complexes exhibiting a variety of synergistic antioxidant activities useful in food, dietary supplements, cosmetics and pharmaceutical formulations. Compositions comprising apple, grape, green tea, and olive extracts are presented herein. In the synergistic formulation, the apple, grape, green tea and olive extracts are used in an amount that provides antioxidant activity or protein kinase modulating activity that is greater than that provided by an equivalent amount of any one of the extracts or the sum of the extracts. Further presented are methods of modulating oxidative stress, disease-related protein kinase activity and enhancing the therapeutic effect of the primary therapeutic agent. Also presented are methods of preparing activity enhancing compositions for modulating oxidative stress, disease-related protein kinase activity and enhancing the therapeutic effect of primary therapeutic agents.